<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575482</url>
  </required_header>
  <id_info>
    <org_study_id>CTP140105HT4</org_study_id>
    <nct_id>NCT02575482</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-D4010 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single and multiple ascending dose study to assess the safety, tolerability and
      pharmacokinetics of SUVN-D4010 administered orally once a day to healthy male subjects. The
      study will be conducted under double blind conditions.

      The primary objective is to evaluate the safety and tolerability of SUVN-D4010 following oral
      administration of single or multiple ascending doses and estimate the maximum tolerated dose
      of SUVN-D4010,if possible.

      The secondary objectives are to evaluate the single and repeat dose plasma pharmacokinetics
      following oral administration of single and multiple ascending doses of SUVN-D4010 in healthy
      male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Range of Day 1-17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical exams</measure>
    <time_frame>Range of Day 1-17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitals signs</measure>
    <time_frame>Range of Day 1-17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CSSRS (suicidality)</measure>
    <time_frame>Range of Day 1-17</time_frame>
    <description>Columbia Suicidal Severity Rating Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single or multiple doses of SUVN-D4010 in healthy male subjects</measure>
    <time_frame>Range of Day 1-17</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events, Laboratory parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the SUVN-D4010 plasma concentrationtime curve in a dosing interval (AUC0tau)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SUVN-D4010 plasma concentrationtime curve from zero to infinity (AUC0inf)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) and time of observation (tmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index following multiple dosing of SUVN-D4010 (AI)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (tÂ½)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Single and Multiple ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SUVN-D4010 in healthy male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in healthy male subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUVN-D4010</intervention_name>
    <arm_group_label>Single and Multiple ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).

        Exclusion Criteria:

          -  Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the volunteer at risk because of participation in the
             study, or influence the results or the volunteer's ability to participate

          -  History or presence of GI, hepatic, or renal disease or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs as judged
             by Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dickerson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUVN-D4010</keyword>
  <keyword>serotonin 4 (5-HT4) receptor</keyword>
  <keyword>first in human</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>tolerability</keyword>
  <keyword>single dose</keyword>
  <keyword>repeat dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

